SEC Filing Summary: Merck & Co., Inc. (13F-HR)
Business Context and Reporting Period
This Form 13F-HR is a quarterly holdings report filed by Merck & Co., Inc. as an Institutional Investment Manager. The report covers the period ended March 31, 2026, and was signed on May 13, 2026. The filing includes holdings for Merck & Co., Inc. and one other included manager, Merck Sharp & Dohme LLC.
Key Financial Metrics
As a 13F filing, this document reports equity holdings rather than the company's operational financial performance (revenue, profit, cash flow, or debt). The following metrics relate to the reported investment portfolio:
- Total Value of Reported Holdings: $349,437,632
- Total Number of Holdings Entries: 14
- Number of Other Included Managers: 1
Note: The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity for Merck & Co., Inc. as an operating entity.
Material Changes
The filing text does not provide comparative data for the prior period (e.g., December 31, 2025) to determine material changes in holdings value or composition. The report is marked as a standard 13F Holdings Report, not an amendment or restatement.
Guidance, Outlook, and Risks
This filing type does not contain management commentary, forward-looking guidance, risk factors, or contingencies regarding the company's business operations. It strictly discloses the equity securities held by the reporting manager at the end of the quarter.
Investor Verification Checklist
- Verify the total portfolio value of $349,437,632 against the sum of individual holdings in the full schedule (not provided in this summary text).
- Confirm the inclusion of Merck Sharp & Dohme LLC (CIK: 0000064978) as a related manager.
- Note that this filing reflects 14 distinct equity positions held by the manager.
- Recognize that this document does not reflect Merck & Co., Inc.'s own financial health or operational results.